Last Price
0.005
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Overview
Market Cap
0
Shares Outstanding
0
Avg Volume
0
Avg Price (50 Days)
0.00
Avg Price (200 Days)
0.00
PE Ratio
0.00
EPS
0.00
Earnings Announcement
Previous Close
0.00
Open
0.00
Day's Range
0.0 - 0.0
Year Range
0.0 - 0.0
Trading Volume
0
Price Change Highlight
1 Day Change
5 Day Change
1 Month Change
3 Month Change
6 Month Change
Ytd Change
1 Year Change
3 Year Change
5 Year Change
10 Year Change
Max Change
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Anatara Lifesciences Limited engages in the research, development, and commercializing of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and 3FDC for the treatment of anxiety, stress, or depression. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry water. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Latest Videos
![[New IPO] Hartanah Kenyalang Berhad, a key construction player in Sarawak, focuses on institutional buildings and infrastructure projects, plans to list on the Ace Market!](https://mqac.i3investor.com/img/video_thumbnail/1152/Thumbnail__(3).png)
.jpg)
![[New IPO] Signature Alliance Berhad](https://mqac.i3investor.com/img/video_thumbnail/1143/Thumbnail__(2).png)
.jpg)
Apps
Top Articles
Daily Stocks
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
